Q2 EPS Estimates for iTeos Therapeutics Cut by Wedbush

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Investment analysts at Wedbush decreased their Q2 2025 earnings per share (EPS) estimates for shares of iTeos Therapeutics in a report issued on Monday, April 28th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.85) for the quarter, down from their previous forecast of ($0.80). Wedbush has a “Outperform” rating and a $25.00 price objective on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.49) per share. Wedbush also issued estimates for iTeos Therapeutics’ Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.88) EPS, FY2025 earnings at ($3.35) EPS, Q1 2026 earnings at ($0.98) EPS, Q2 2026 earnings at ($1.03) EPS, Q3 2026 earnings at ($1.08) EPS, Q4 2026 earnings at ($1.10) EPS, FY2026 earnings at ($4.19) EPS, FY2027 earnings at ($4.79) EPS, FY2028 earnings at ($4.55) EPS and FY2029 earnings at ($3.20) EPS.

Other equities analysts have also recently issued reports about the stock. JPMorgan Chase & Co. dropped their target price on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday, March 6th. Wells Fargo & Company decreased their target price on shares of iTeos Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $46.00 price objective on shares of iTeos Therapeutics in a report on Thursday, March 6th.

iTeos Therapeutics Stock Performance

Shares of NASDAQ ITOS opened at $7.50 on Thursday. The stock has a market capitalization of $286.46 million, a P/E ratio of -2.38 and a beta of 1.43. The stock’s fifty day moving average is $6.57 and its 200 day moving average is $7.55. iTeos Therapeutics has a 52 week low of $4.80 and a 52 week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.14.

Institutional Trading of iTeos Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in iTeos Therapeutics by 3.2% during the third quarter. Geode Capital Management LLC now owns 640,350 shares of the company’s stock worth $6,540,000 after buying an additional 20,092 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of iTeos Therapeutics during the 3rd quarter worth approximately $102,000. JPMorgan Chase & Co. increased its stake in shares of iTeos Therapeutics by 1.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 467,319 shares of the company’s stock valued at $4,771,000 after acquiring an additional 5,368 shares in the last quarter. Marquette Asset Management LLC acquired a new position in shares of iTeos Therapeutics during the 4th quarter valued at $122,000. Finally, Clear Harbor Asset Management LLC acquired a new stake in iTeos Therapeutics in the fourth quarter worth $96,000. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.